Comparable stake leader
Alison Mosca
SEC ownership of Clene Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001822791.
Disclosed value leader
Chidozie Ugwumba
Comparable rows
36/50
Latest evidence
11 Jun 2026
- Public ticker
- CLNN on Nasdaq
- Parsed ownership sources
-
3/4/5, 13D/G, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Alison Mosca
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
36 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Alison Mosca
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
11 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001822791
- Issuer location
- Salt Lake City, UT
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Clene Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Alison Mosca
Disclosed value leader
Chidozie Ugwumba
Comparable rows
36/50
Latest evidence
11 Jun 2026
3/4/5
13D/G
13F
Lead comparable stake: 13%
14 rows are not safely comparable across share classes.
13D/G row: Alison Mosca
Showing 1-8 of 50 holder rows.
Quick read
Alison Mosca leads the comparable SEC ownership view at 13%.
36 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Alison Mosca's linked filing trail.
Comparable ownership
Top 5
Alison Mosca
13%
Vivo Opportunity Fund Holdings, L.P.
10%
Chidozie Ugwumba
9.7%
4LIFE RESEARCH LLC
6.5%
ARMISTICE CAPITAL, LLC
5%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Alison Mosca |
3/4/5
13D/G
Director
|
13%
from 13D/G
|
$3,005,527
708,315 shares
mixed-class rows
|
— | 21 May 2026 |
| Vivo Opportunity Fund Holdings, L.P. |
13D/G
|
10%
|
—
1,886,469 shares
|
$0 | 31 Mar 2026 |
| Chidozie Ugwumba |
13D/G
3/4/5
Ugwumba Chidozie · 10%+ Owner
|
9.7%
|
$7,782,169
1,351,071 shares
|
-$3,251,975 | 11 May 2026 |
| 4LIFE RESEARCH LLC |
13D/G
David Lisonbee
|
6.5%
|
$84,921
555,328 shares
|
$0 | 20 Dec 2024 |
| ARMISTICE CAPITAL, LLC |
13D/G
|
5%
|
$1,257,303
419,101 shares
|
$0 | 31 Dec 2024 |
| AWM Investment Company, Inc. |
13D/G
|
4.7%
|
$3,012,500
500,000 shares
|
$0 | 30 Sep 2025 |
| General Resonance LLC |
3/4/5
10%+ Owner
|
5.1%
|
$3,762,515
704,591 shares
|
-$18,161 | 21 Aug 2025 |
| Boxer Capital Management, LLC |
13F
Company
|
3.4%
|
$2,354,149
477,515 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$5,582,658.
Buys
$216,664
Insiders: 1
Sells
$5,799,322
Insiders: 2
Net
-$5,582,658
Shares: -941,890
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 33,333
Shares: 975,223
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 298,474 | $0 | $1,902,330 | -$1,902,330 |
| 3-6 | 33,333 | 355,609 | $216,664 | $1,789,734 | -$1,573,070 |
| 6-9 | 0 | 317,739 | $0 | $2,089,096 | -$2,089,096 |
| 9-12 | 0 | 3,401 | $0 | $18,161 | -$18,161 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-17 of 17 reporting-owner rows connected to Clene Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
17
Largest Forms 3/4/5 holder
General Resonance LLC
Net 12M change
-$5,582,657
Latest report
11 Jun 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| General Resonance LLC | 10%+ Owner | $3,762,515 | -$18,161 | -0.48% | Filing P/S | 21 Aug 2025 |
| David J. Matlin | Director | $3,105,856 | +$216,665 | +7.5% | Filing P/S | 21 May 2026 |
| Alison Mosca | Director | $3,005,527 | Mixed | 21 May 2026 | ||
| Chidozie Ugwumba | 10%+ Owner | $641,185 | -$5,781,161 | -90% | Filing P/S | 01 May 2026 |
| Morgan R. Brown | Chief Financial Officer | $53,800 | Mixed | 11 Jun 2026 | ||
| Robert Glanzman | Chief Medical Officer | $4,331 | Mixed | 16 May 2022 | ||
| Shalom Jacobovitz | Director | Mixed | 21 May 2026 | |||
| Matthew Kiernan | Director | Mixed | 21 May 2026 | |||
| Arjun Jj Desai | Director | Mixed | 21 May 2026 | |||
| Reed N. Wilcox | Director | Mixed | 21 May 2026 | |||
| Mark Mortenson | Chief Science Officer | Mixed | 11 Jun 2026 | |||
| Robert Dee Etherington | President & CEO, Director | Mixed | 11 Jun 2026 | |||
| Fiona Costello | Director | Mixed | 18 May 2021 | |||
| Jonathon Gay | Director | Mixed | 21 May 2026 | |||
| Tae Heum Jeong | Chief Finance Officer | Mixed | 04 Nov 2021 | |||
| Vallerie McLaughlin | Director | Mixed | 21 May 2026 | |||
| John Henry Stevens | Director | Mixed | 18 Sep 2023 |
Recent insider transactions for Clene Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Mark Mortenson | CLNN | stock option | Award | 45,000 | 45,000 | 11 Jun 2026 | Direct | |||
| Robert Dee Etherington | CLNN | stock option | Award | 65,000 | 65,000 | 11 Jun 2026 | Direct | |||
| Morgan R. Brown | CLNN | stock option | Award | 15,000 | 15,000 | 11 Jun 2026 | Direct | |||
| Vallerie McLaughlin | CLNN | stock option | Award | 3,564 | 2,064 | 21 May 2026 | Direct | |||
| Arjun Jj Desai | CLNN | stock option | Award | 3,658 | 2,158 | 21 May 2026 | Direct | |||
| Alison Mosca | CLNN | stock option | Award | 4,361 | 2,861 | 21 May 2026 | Direct | |||
| David J. Matlin | CLNN | stock option | Award | 5,159 | 3,659 | 21 May 2026 | Direct | |||
| Shalom Jacobovitz | CLNN | stock option | Award | 4,291 | 2,791 | 21 May 2026 | Direct | |||
| Matthew Kiernan | CLNN | stock option | Award | 3,376 | 1,876 | 21 May 2026 | Direct | |||
| Jonathon Gay | CLNN | stock option | Award | 3,728 | 2,228 | 21 May 2026 | Direct | |||
| Reed N. Wilcox | CLNN | stock option | Award | 3,564 | 2,064 | 21 May 2026 | Direct | |||
| Chidozie Ugwumba | CLNN | Common Stock | Sale | -41.5% | $454,435 | $6.20 | -73,296 | 103,417 | 12 May 2026 | By SymBiosis II, LLC |
| Chidozie Ugwumba | CLNN | Common Stock | Sale | -11.2% | $149,695 | $6.75 | -22,177 | 176,713 | 11 May 2026 | By SymBiosis II, LLC |
| Chidozie Ugwumba | CLNN | Common Stock | Sale | -26.8% | $495,611 | $6.80 | -72,884 | 198,890 | 04 May 2026 | By SymBiosis II, LLC |
| Chidozie Ugwumba | CLNN | Common Stock | Sale | -2.09% | $34,828 | $6.01 | -5,795 | 271,774 | 01 May 2026 | By SymBiosis II, LLC |
| Chidozie Ugwumba | CLNN | Common Stock | Sale | -2.02% | $34,875 | $6.08 | -5,736 | 277,569 | 30 Apr 2026 | By SymBiosis II, LLC |
| Chidozie Ugwumba | CLNN | Common Stock | Sale | -4.12% | $68,517 | $5.63 | -12,170 | 283,305 | 29 Apr 2026 | By SymBiosis II, LLC |
| Chidozie Ugwumba | CLNN | Common Stock | Sale | -0.54% | $9,387 | $5.90 | -1,591 | 295,475 | 28 Apr 2026 | By SymBiosis II, LLC |
| Chidozie Ugwumba | CLNN | Common Stock | Sale | -17.1% | $376,658 | $6.14 | -61,345 | 297,066 | 21 Apr 2026 | By SymBiosis II, LLC |
| Chidozie Ugwumba | CLNN | Common Stock | Sale | -1.19% | $26,426 | $6.12 | -4,318 | 358,411 | 20 Apr 2026 | By SymBiosis II, LLC |
| Chidozie Ugwumba | CLNN | Common Stock | Sale | -6.46% | $161,007 | $6.43 | -25,040 | 362,729 | 17 Apr 2026 | By SymBiosis II, LLC |
| Chidozie Ugwumba | CLNN | Common Stock | Sale | -1.96% | $49,587 | $6.40 | -7,748 | 387,769 | 16 Apr 2026 | By SymBiosis II, LLC |
| Chidozie Ugwumba | CLNN | Common Stock | Sale | -1.59% | $41,304 | $6.48 | -6,374 | 395,517 | 15 Apr 2026 | By SymBiosis II, LLC |
| Chidozie Ugwumba | CLNN | Common Stock | Sale | -5.84% | $119,889 | $4.81 | -24,925 | 401,891 | 02 Apr 2026 | By SymBiosis II, LLC |
| Chidozie Ugwumba | CLNN | Common Stock | Sale | -0.99% | $21,262 | $4.97 | -4,278 | 426,816 | 01 Apr 2026 | By SymBiosis II, LLC |
| Chidozie Ugwumba | CLNN | Common Stock | Sale | -13.6% | $331,796 | $4.88 | -67,991 | 431,094 | 31 Mar 2026 | By Symbiosis II, LLC |
| Chidozie Ugwumba | CLNN | Common Stock | Sale | -3.02% | $79,234 | $5.10 | -15,536 | 499,085 | 30 Mar 2026 | By SymBiosis II, LLC |
| Chidozie Ugwumba | CLNN | Common Stock | Sale | -3.28% | $82,982 | $4.75 | -17,470 | 514,621 | 27 Mar 2026 | By SymBiosis II, LLC |
| Chidozie Ugwumba | CLNN | Common Stock | Sale | -0.99% | $28,723 | $5.40 | -5,319 | 532,091 | 26 Mar 2026 | By SymBiosis II, LLC |
| Chidozie Ugwumba | CLNN | Common Stock | Sale | -1.3% | $39,039 | $5.50 | -7,098 | 537,410 | 25 Mar 2026 | By SymBiosis II, LLC |
| Chidozie Ugwumba | CLNN | Common Stock | Sale | -1% | $31,744 | $5.78 | -5,492 | 544,508 | 24 Mar 2026 | By SymBiosis II, LLC |
| Vallerie McLaughlin | CLNN | stock option | Award | 3,030 | 3,030 | 19 Feb 2026 | Direct | |||
| Reed N. Wilcox | CLNN | stock option | Award | 3,306 | 3,306 | 19 Feb 2026 | Direct | |||
| Alison Mosca | CLNN | stock option | Award | 4,201 | 4,201 | 19 Feb 2026 | Direct | |||
| David J. Matlin | CLNN | stock option | Award | 5,372 | 5,372 | 19 Feb 2026 | Direct | |||
| Arjun Jj Desai | CLNN | stock option | Award | 3,168 | 3,168 | 19 Feb 2026 | Direct | |||
| Shalom Jacobovitz | CLNN | stock option | Award | 4,098 | 4,098 | 19 Feb 2026 | Direct | |||
| Jonathon Gay | CLNN | stock option | Award | 3,271 | 3,271 | 19 Feb 2026 | Direct | |||
| Matthew Kiernan | CLNN | stock option | Award | 2,755 | 2,755 | 19 Feb 2026 | Direct | |||
| Chidozie Ugwumba | CLNN | Common Stock | Sale | -1% | $22,792 | $4.10 | -5,559 | 550,000 | 03 Feb 2026 | By Symbiosis II, LLC |
| Chidozie Ugwumba | CLNN | Common Stock | Sale | -0.68% | $15,352 | $4.04 | -3,800 | 555,559 | 02 Feb 2026 | By SymBiosis II, LLC |
| Chidozie Ugwumba | CLNN | Common Stock | Sale | -1.01% | $23,483 | $4.13 | -5,686 | 559,359 | 30 Jan 2026 | By Symbiosis II, LLC |
| Chidozie Ugwumba | CLNN | Common Stock | Sale | -2.63% | $66,027 | $4.32 | -15,284 | 565,045 | 29 Jan 2026 | By Symbiosis II, LLC |
| Chidozie Ugwumba | CLNN | Common Stock | Sale | -1.48% | $42,800 | $4.91 | -8,717 | 580,329 | 28 Jan 2026 | By SymBiosis II, LLC |
| Chidozie Ugwumba | CLNN | Common Stock | Sale | -0.7% | $21,026 | $5.08 | -4,139 | 589,046 | 27 Jan 2026 | By Symbiosis II, LLC |
| Chidozie Ugwumba | CLNN | Common Stock | Sale | -1.07% | $32,218 | $5.02 | -6,418 | 593,185 | 26 Jan 2026 | By Symbiosis II, LLC |
| Chidozie Ugwumba | CLNN | Common Stock | Sale | -0.92% | $29,280 | $5.27 | -5,556 | 599,603 | 23 Jan 2026 | By Symbiosis II, LLC |
| Chidozie Ugwumba | CLNN | Common Stock | Sale | -2.05% | $67,378 | $5.32 | -12,665 | 605,159 | 22 Jan 2026 | By Symbiosis II, LLC |
| Mark Mortenson | CLNN | stock option | Award | 75,000 | 75,000 | 22 Jan 2026 | Direct | |||
| Robert Dee Etherington | CLNN | stock option | Award | 75,000 | 75,000 | 22 Jan 2026 | Direct |
* marks a reported price that did not pass the local price check.